Review of vaccine effectiveness assumptions used in economic evaluations of infant pneumococcal conjugate vaccine

Impact of protein D-containing pneumococcal conjugate vaccines on non-typeable Haemophilus influenzae acute otitis media and carriage

(2017) Christopher Clarke et al.   Expert Review of Vaccines

Streptococcus pneumoniae serotype 19A: worldwide epidemiology

(2017) Raul Isturiz et al.   Expert Review of Vaccines

Direct and Indirect Effectiveness of the 10-Valent Pneumococcal Conjugate Vaccine Against Carriage in a Cluster Randomized Trial

(2017) Arto A. Palmu et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Surveillance of impact of PCV-10 vaccine on pneumococcal meningitis in Mozambique, 2013 – 2015

(2017) Aquino Albino Nhantumbo et al.   PLoS One

Indirect effects of childhood pneumococcal conjugate vaccination on invasive pneumococcal disease: a systematic review and meta-analysis

(2017) Tinevimbo Shiri et al.   Lancet Global Health

Direct and indirect impact of 10-valent pneumococcal conjugate vaccine introduction on pneumonia hospitalizations and economic burden in all age-groups in Brazil: A time-series analysis

(2017) Ana Lucia Andrade et al.   PLoS One

Prevention of early episodes of otitis media by pneumococcal vaccines might reduce progression to complex disease

(2016) Ron Dagan et al.   LANCET INFECTIOUS DISEASES

Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review

(2016) Surasak Saokaew et al.   PHARMACOECONOMICS

Pneumococcal vaccine impact on otitis media microbiology: A New Zealand cohort study before and after the introduction of PHiD-CV10 vaccine

(2016) Emma J. Best et al.   VACCINE

Vaccine effectiveness of PCV13 in a 3 + 1 vaccination schedule

(2016) Raphael Weinberger et al.   VACCINE

Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model

(2016) Emmanuelle Delgleize et al.   BMJ Open

Evaluating the impact of PCV-10 on invasive pneumococcal disease in Brazil: A time-series analysis

(2016) Ana Lucia Andrade et al.   Human Vaccines & Immunotherapeutics

Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study

(2016) Matthew R Moore et al.   Lancet Respiratory Medicine

Effectiveness of the 10-Valent Pneumococcal NontypeableHaemophilus influenzaeProtein D–Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media—A Double-Blind Randomized Clinical Trial in Finland

(2016) Timo Vesikari et al.   Journal of the Pediatric Infectious Diseases Society

Effectiveness of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) against Invasive Pneumococcal Disease among Children under Two Years of Age in Germany

(2016) Mark van der Linden et al.   PLoS One

Reduced middle ear infection with non-typeable Haemophilus influenzae, but not Streptococcus pneumoniae, after transition to 10-valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine

(2015) Amanda Jane Leach et al.   BMC Pediatrics

Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study

(2015) Pauline A Waight et al.   LANCET INFECTIOUS DISEASES

Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance

(2015) Matthew R Moore et al.   LANCET INFECTIOUS DISEASES

Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children

(2015) David Greenberg et al.   VACCINE

Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001–2012

(2015) A. Lepoutre et al.   VACCINE

Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: A review of economic evaluations (2006–2014)

(2015) David Bin-Chia Wu et al.   VACCINE

The Health And Medical Care Costs For Hospitalized All-Cause Pneumonia Among Children

(2015) A Berglund et al.   VALUE IN HEALTH

Impact of Ten-Valent Pneumococcal Conjugate Vaccination on Invasive Pneumococcal Disease in Finnish Children – A Population-Based Study

(2015) Jukka Jokinen et al.   PLoS One

Do Pneumococcal Conjugate Vaccines Represent Good Value for Money in a Lower-Middle Income Country? A Cost-Utility Analysis in the Philippines

(2015) Manuel Alexander Haasis et al.   PLoS One

Direct Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants

(2015) Alienke J. Wijmenga-Monsuur et al.   PLoS One

Impact of 13-Valent Pneumococcal Conjugate Vaccination in Invasive Pneumococcal Disease Incidence and Mortality

(2014) Zitta Barrella Harboe et al.   CLINICAL INFECTIOUS DISEASES

Efficacy of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus That of 7-Valent PCV (PCV7) Against Nasopharyngeal Colonization of Antibiotic-NonsusceptibleStreptococcus pneumoniae

(2014) Ron Dagan et al.   JOURNAL OF INFECTIOUS DISEASES

Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study

(2014) Nick J Andrews et al.   LANCET INFECTIOUS DISEASES

Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children

(2014) Shalom Ben-Shimol et al.   VACCINE

Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial

(2014) Miguel W. Tregnaghi et al.   PLOS MEDICINE

Effect of 13-valent pneumococcal conjugate vaccine on admissions to hospital 2 years after its introduction in the USA: a time series analysis

(2014) Lone Simonsen et al.   Lancet Respiratory Medicine

Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study

(2014) Carla Magda Allan S Domingues et al.   Lancet Respiratory Medicine

Cost-Effectiveness of a 10- Versus 13-Valent Pneumococcal Conjugate Vaccine in Denmark and Sweden

(2013) Rogier M. Klok et al.   CLINICAL THERAPEUTICS

Global burden of childhood pneumonia and diarrhoea

(2013) Christa L Fischer Walker et al.   LANCET

U.S. Hospitalizations for Pneumonia after a Decade of Pneumococcal Vaccination

(2013) Marie R. Griffin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cost-utility analysis of 10- and 13-valent pneumococcal conjugate vaccines: Protection at what price in the Thai context?

(2013) Wantanee Kulpeng et al.   VACCINE

Serotype prevalence and antibiotic resistance in Streptococcus pneumoniae clinical isolates among global populations

(2013) M. Hackel et al.   VACCINE

Prompt effect of replacing the 7-valent pneumococcal conjugate vaccine with the 13-valent vaccine on the epidemiology of invasive pneumococcal disease in Norway

(2013) Anneke Steens et al.   VACCINE

Cost-effectiveness of 2 + 1 dosing of 13-valent and 10-valent pneumococcal conjugate vaccines in Canada

(2012) Stephanie R Earnshaw et al.   BMC INFECTIOUS DISEASES

Acute Otitis Media Replacement and Recurrence in the Finnish Otitis Media Vaccine Trial

(2012) J. Jokinen et al.   CLINICAL INFECTIOUS DISEASES

Effects of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugate Vaccine on Nasopharyngeal Bacterial Colonization in Young Children: A Randomized Controlled Trial

(2012) M. R. van den Bergh et al.   CLINICAL INFECTIOUS DISEASES

Comparing Health Outcomes and Costs of General Vaccination with Pneumococcal Conjugate Vaccines in Sweden: A Markov Model

(2012) Åsa By et al.   CLINICAL THERAPEUTICS

Cost–effectiveness models of pneumococcal conjugate vaccines: variability and impact of modeling assumptions

(2012) Raymond A Farkouh et al.   Expert Review of Vaccines

Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial

(2012) Arto A Palmu et al.   LANCET

The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England

(2012) Albert Jan van Hoek et al.   VACCINE

Cost-Effectiveness Analysis of Pneumococcal Conjugate Vaccine in Taiwan: A Transmission Dynamic Modeling Approach

(2012) David Bin-Chia Wu et al.   VALUE IN HEALTH

Cost-effectiveness of 13-valent pneumococcal conjugate vaccine: Germany, Greece, and The Netherlands

(2011) David R. Strutton et al.   JOURNAL OF INFECTION

The Impact of the Heptavalent Pneumococcal Conjugate Vaccine on the Epidemiology of Acute Otitis Media Complicated by Otorrhea

(2011) Kostantinos Stamboulidis et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: Comparing estimates for 7-valent, 10-valent, and 13-valent vaccines

(2011) Karen Richards Tyo et al.   VACCINE

Evaluación Económica de un Programa de Inmunización Infantil en México Basado en la Vacuna Neumocócica Conjugada 13-Valente

(2011) Emilio Muciño-Ortega et al.   VALUE IN HEALTH

Health and economic impact of PHiD-CV in Canada and the UK: a Markov modelling exercise

(2011) Gerhart Knerer et al.   JOURNAL OF MEDICAL ECONOMICS

Dynamic models of pneumococcal carriage and the impact of the Heptavalent Pneumococcal Conjugate Vaccine on invasive pneumococcal disease

(2010) Alessia Melegaro et al.   BMC INFECTIOUS DISEASES

Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A?

(2010) William P Hausdorff et al.   BMC Pediatrics

Immunogenicity and Reactogenicity of a 13-Valent-pneumococcal Conjugate Vaccine Administered at 2, 4, and 12 Months of Age

(2010) Matthew D. Snape et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Outcomes and costs associated with PHiD-CV, a new protein D conjugate pneumococcal vaccine, in four countries

(2010) Sandra E. Talbird et al.   VACCINE

Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States

(2010) Jaime L. Rubin et al.   VACCINE

Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany

(2010) Dorothee M. Kieninger et al.   VACCINE

Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae

(2009) R. Dagan   CLINICAL MICROBIOLOGY AND INFECTION

Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine

(2009) Tamara Pilishvili et al.   JOURNAL OF INFECTIOUS DISEASES

Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae-derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2 years of age

(2009) Roman Prymula et al.   VACCINE

Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era

(2008) Ener Cagri Dinleyici et al.   Expert Review of Vaccines